ClinicalTrials.gg
CompletedNCT00842088Updated Aug 1, 2011

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

A Phase 1/2 interventional study of Placebo and HQK-1001 in Sickle Cell Disease, sponsored by HemaQuest Pharmaceuticals Inc.. Completed at 9 sites in 2 countries. Open to participants aged 12 Years to 60 Years. Per ClinicalTrials.gov, last updated 2011-08-01.

Sponsored by HemaQuest Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
12 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
338th of 559
24 · median 31
Started
2009
with 25 others
Phase 1/2
60 of 733
13 open now
Registered
112th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 338th largest by enrollment of the 559 interventional ones that give a count, is one of 26 that started in 2009, is one of 60 in phase 1/2, and was the 112th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of HQK-1001 administered for a total of 12 weeks (with one dosing break) in subjects with sickle cell disease.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
12 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of SCD or sickle beta thalassemia (excluding C)
  • Between 12 and 60 years of age, inclusive
  • At least one episode of a SCD-related crisis or complication (e.g., vaso-occlusive crisis, acute chest syndrome, priapism) per year for an average of 3 years or one episode of acute chest syndrome over the prior 5 years
  • Screening (untransfused) HbF level >/= 2% as analyzed by a central laboratory
  • If receiving hydroxyurea therapy, must be receiving a stable dose for at least 6 months
  • Able and willing to give
  • If female, must have a negative serum pregnancy test within 7 days of dosing
  • If female, must not be of defined as by at least 2 years or surgically sterile, or must agree to use a medically accepted form of throughout the study
  • If the sexual partner of a male subject is a WCBP, she must agree to use a medically accepted form of birth control for themselves or their partner throughout the study
  • In the view of the Investigator, able to comply with necessary study procedures

Exclusion criteria

Exclusion Criteria:

  • Red blood cell (RBC) transfusion within 3 months prior to beginning study medication
  • Participation in a regular blood transfusion program
  • More than 4 hospitalizations for acute sickle cell-related events in the previous 12 months
  • An acute vaso-occlusive event within 3 weeks prior to receiving first dose of study medication
  • Pulmonary hypertension requiring oxygen
  • > 450 msec on screening
  • (ALT) > 3X (ULN)
  • Creatinine phosphokinase (CPK) > 20% above the ULN
  • Serum creatinine >1.2 mg/dL
  • An acute illness (e.g., febrile, gastrointestinal [GI], respiratory) within 72 hours prior to receiving first dose of study medication
  • History of syncope, dysrhythmias or resuscitation from sudden death
  • Chronic opiate use which, in the view of the Investigator, could confound evaluation of an drug
  • Current abuse of alcohol or drugs
  • Received another investigational agent within 4 weeks, or 5 half-lives, whichever is longer, prior to administration of study medication
  • Currently pregnant or breast feeding a child
  • Known infection with -1
  • Infection with or such that patients are currently on therapy or will be placed on therapy during the trial
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Active

    Drug: HQK-1001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugPlacebo

    Matching placebo capsule. Administered orally once a day on dosing days.

  • DrugDimebutic acidStudies of Dimebutic acidDimebutic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.

06

What researchers measure

Primary outcomes

  1. Safety as assessed by (1) adverse events (2) laboratory values (3) vital signs, and (4) physical exam.

    Time frame: 126 days

Secondary outcomes

  1. Pharmacokinetics assessed by plasma drug concentration levels.

    Time frame: Days 0, 6, 69 and 97 post first dose

  2. Pharmacodynamics assessed by red blood cell production and induction of fetal hemoglobin.

    Time frame: Every 2 weeks through Day 126 post first dose

07

Study locations

9 sites
  • Trialogic Research
    Madison, Alabama 35758, United States
  • Children's Hospital and Research Center at Oakland
    Oakland, California 94609, United States
  • Century Clinical Research, Inc.
    Daytona Beach, Florida 32117, United States
  • Medical College of Georgia
    Augusta, Georgia 30912, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21205, United States
  • UNC Comprehensive Sickle Cell Program
    Chapel Hill, North Carolina 27599, United States
  • Texas Children's Cancer Center and Hematology Service
    Houston, Texas 77030, United States
  • University of the West Indies, Mona
    Kingston, Mona 7, Jamaica
08

References and documents

Publications

  • Kutlar A, Ataga K, Reid M, Vichinsky EP, Neumayr L, Blair-Britt L, Labotka R, Glass J, Keefer JR, Wargin WA, Berenson R, Perrine SP. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2012 Nov;87(11):1017-21. doi: 10.1002/ajh.23306. Epub 2012 Aug 7. PubMed 22887019 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009 and a primary completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2009
First posted
Feb 12, 2009
Start
Mar 2009
Primary completionActual
Jul 2010
Results delay requested
Jul 1, 2011
Last update
Aug 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00842088
Lead sponsor
HemaQuest Pharmaceuticals Inc.
First posted
Feb 12, 2009
Start date
Mar 2009
Primary completion
Jul 2010
Last update
Aug 1, 2011

Study contacts

Susan Perrine, M.D.
study director · HemaQuest Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimebutic acid

Start the discussion